Product Profiles: Stroke Prevention in Atrial Fibrillation - Uptake slower than expected for the first warfarin alternatives, the novel oral anticoagulants

Description:

This report provides analysis of key oral anticoagulants brands and pipeline agents for stroke prevention in atrial fibrillation (SPAF) across the seven major markets, including a comparative evaluation of clinical and commercial drug attributes.

The difficulties with using the standard therapy, warfarin, in this indication have led to the development of the novel oral anticoagulants. Uptake of the two marketed novel therapies, Pradaxa and Xarelto, has been slower than expected. However, the pipeline drug Eliquis has the potential to expand oral anticoagulant usage beyond its traditional patient population.

Scope

- Understand Datamonitor's independent appraisal of marketed oral anticoagulant brands and key pipeline agents indicated for treating SPAF.
- Illustrate how pipeline and marketed oral anticoagulants compare in terms of clinical and commercial attributes.
- Review important clinical developments for the key pipeline agents with analysis of the latest clinical trial data.
- Determine to what extent the key pipeline drug Eliquis (apixaban) satisfies the main clinical unmet needs in SPAF.

Highlights

- Despite the difficulties with warfarin usage, the widely genericized drug is holding its own against the novel oral anticoagulants due to its much lower price point in comparison to branded Pradaxa and Xarelto.
- The marketed novel oral anticoagulants, Pradaxa and Xarelto, have faced slower than expected uptake due to physician uncertainty over bleeding risks in a clinical setting and the lack of an antidote.
- The pipeline candidate Eliquis, which is expected in Q1 2013, has the potential to become best-in-class based on strong Phase III efficacy and safety trial data.

Reasons to Purchase

- How are the marketed oral anticoagulants positioned in SPAF?
- How will the pipeline candidates impact on the way SPAF is managed?
- What are the comparative strengths and weaknesses of the key oral anticoagulants and pipeline candidates?
- How has the clinical development of an antidote to the novel oral anticoagulants progressed?
- What impact will the novel oral anticoagulants have on the current therapy options, warfarin and aspirin?

Contents:

OVERVIEW
- Catalyst
- Summary

EXECUTIVE SUMMARY
- Strategic scoping and focus
PRODUCT OVERVIEW
- Stroke prevention in atrial fibrillation
- Key marketed and pipeline products

MARKETED PRODUCT PROFILES
- Warfarin (Coumadin; DuPont)
  - Drug profile
  - Development overview
  - SWOT analysis
  - Product positioning
  - Clinical and commercial attractiveness
- Pradaxa (dabigatran; Boehringer Ingelheim)
  - Drug Profile
  - Development overview
  - SWOT analysis
  - Product positioning
  - Clinical and commercial attractiveness
- Xarelto (rivaroxaban; Bayer/Johnson & Johnson)
  - Drug profile
  - Development overview
  - SWOT analysis
  - Product positioning
  - Clinical and commercial attractiveness
- Other marketed drugs for stroke prevention in atrial fibrillation
  - Aspirin (widely genericized)
  - Plavix (clopidogrel; Sanofi)
  - Unfractionated heparin (heparin sodium; widely genericized)
  - Low molecular weight heparin

PIPELINE PRODUCT PROFILES
- Eliquis (apixaban; Bristol-Myers Squibb/Pfizer)
  - Drug profile
  - Development overview
  - SWOT analysis
  - Satisfaction of unmet needs
  - Clinical and commercial attractiveness
- Other drugs in development for stroke prevention in atrial fibrillation
  - Lixiana (edoxaban; Daiichi Sankyo)

BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports

APPENDIX
- Market definition
- PharmaVitae Explorer database
- Datamonitor drug assessment scorecard
- Contributing experts

TABLES
Table: Key marketed and pipeline products for SPAF, 2012
Table: Warfarin (Coumadin; DuPont) – drug profile 2012
Table: Overview of pivotal trial data for warfarin in SPAF, 2012
Table: Datamonitor drug assessment summary of warfarin (Coumadin; DuPont) for stroke prevention in atrial fibrillation, 2012
Table: Pradaxa (dabigatran; Boehringer Ingelheim) – drug profile, 2012
Table: Overview of pivotal trial data for Pradaxa in SPAF, 2012
Table: Datamonitor drug assessment summary of Pradaxa (dabigatran; Boehringer Ingelheim) for stroke prevention in atrial fibrillation, 2012
Table: Xarelto (rivaroxaban; Bayer) – drug profile, 2012
Table: Overview of pivotal trial data for Xarelto in SPAF, 2012
Table: Datamonitor drug assessment summary of Xarelto (rivaroxaban; Bayer/Johnson & Johnson) for stroke prevention in atrial fibrillation, 2012
Table: Aspirin – drug profile, 2012
Table: Overview of pivotal trial data for aspirin in SPAF, 2012
Table: Plavix (clopidogrel; Sanofi) – drug profile, 2012
Table: Overview of pivotal trial data for Plavix (clopidogrel) in SPAF, 2012
Table: Unfractionated heparin (heparin sodium; widely genericized) – drug profile, 2012
Table: Overview of pivotal trial data for unfractionated heparin in SPAF, 2012
Table: Lovenox (enoxaparin; Sanofi) – drug profile, 2012
Table: Overview of pivotal trial data for low molecular weight heparin in SPAF, 2012
Table: Eliquis (apixaban; Bristol-Myers Squibb/Pfizer) – drug profile, 2012
Table: Overview of pivotal trial data for Eliquis in SPAF, 2012
Table: Eliquis vs the minimum acceptable product profile and target product profile, 2012
Table: Datamonitor drug assessment summary of Eliquis (apixaban; Pfizer/Bristol-Myers Squibb) for stroke prevention in atrial fibrillation, 2012
Table: Lixiana (edoxaban; Daiichi Sankyo) – drug profile, 2012
Table: Clinical trial summary of Lixiana in SPAF, 2012
Table: Summary of therapeutic classes used for stroke prevention in atrial fibrillation by ATC code, 2012
Table: Summary of the ICD-10 codes used to define the stroke prevention in atrial fibrillation market
Table: Datamonitor drug assessment parameters for Stroke prevention in atrial fibrillation, 2012

FIGURES

Figure: The targets of marketed and pipeline oral anticoagulants in the coagulation cascade, 2012
Figure: Warfarin (Coumadin; DuPont) – SWOT analysis, 2012
Figure: Datamonitor drug assessment summary of warfarin (Coumadin; DuPont) for stroke prevention in atrial fibrillation, 2012
Figure: Pradaxa (dabigatran) – SWOT analysis, 2012
Figure: Datamonitor drug assessment summary of Pradaxa (dabigatran; Boehringer Ingelheim) for stroke prevention in atrial fibrillation, 2012
Figure: Xarelto (rivaroxaban) – SWOT analysis, 2012
Figure: Datamonitor drug assessment summary of Xarelto (rivaroxaban; Bayer/Johnson & Johnson) for stroke prevention in atrial fibrillation, 2012
Figure: Aspirin (widely genericized) – SWOT analysis, 2012
Figure: Plavix (clopidogrel) – SWOT analysis, 2012
Figure: Unfractionated heparin – SWOT analysis, 2012
Figure: Low molecular weight heparin – SWOT analysis, 2012
Figure: Eliquis (apixaban) – SWOT analysis, 2012
Figure: Datamonitor drug assessment summary of Eliquis (apixaban; Bristol-Myers Squibb/Pfizer) for stroke prevention in atrial fibrillation, 2012
Figure: Lixiana (edoxaban) – SWOT analysis, 2012
Figure: The PharmaVitae Explorer

Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Product Profiles: Stroke Prevention in Atrial Fibrillation - Uptake slower than expected for the first warfarin alternatives, the novel oral anticoagulants
Web Address: http://www.researchandmarkets.com/reports/2236696/
Office Code: SCD2KD7F

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Electronic (PDF) - Single User</td>
<td>USD 11400</td>
</tr>
<tr>
<td></td>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 28500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐</th>
<th>Mrs ☐</th>
<th>Dr ☐</th>
<th>Miss ☐</th>
<th>Ms ☐</th>
<th>Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td>Last Name:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td>Job Title:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td>Address:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td>Phone Number:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
  27-35 Main Street,
  Blackrock,
  Co. Dublin,
  Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World